Monkeypox is the new COVID

Let's watch all these media and national security goons shift gears again

A New Plague to Fear

Isn’t it rather convenient that just after everything started winding down and it looked like COVID-19 was due to become just another endemic flu, a few people out of billions potentially immunocompromised by vaccines just happen to start contracting and sustaining human-to-human transmission of zoonotic illnesses like Monkeypox and Hemorrhagic fever hantavirus that ordinarily have poor transmissibility?

What is Monkeypox, the Virus Infecting People in the U.S. and Europe?

Monkeypox isn’t a new disease. The first confirmed human case was in 1970, when the virus was isolated from a child suspected of having smallpox in the Democratic Republic of Congo (DRC). Monkeypox is unlikely to cause another pandemic, but with COVID-19 top of mind, fear of another major outbreak is understandable. Though rare and usually mild, monkeypox can still potentially cause severe illness. Health officials are concerned that more cases will arise with increased travel.

If it does turn into another pandemic, they'll probably start having people take Jynneos or ACAM2000:

Bavarian Nordic scores FDA nod for smallpox and monkeypox vaccine Jynneos

Sep 25, 2019 07:35am

Bavarian Nordic and the U.S. government have been working for years to advance a next-gen smallpox vaccine, and now the company has scored its much-anticipated approval. The vaccine, Jynneos, represents the first non-replicating smallpox vaccine in the U.S. and the first monkeypox vaccine worldwide. 

Importantly, Jynneos is also the first smallpox vaccine for people with compromised immune systems, such as people with eczema, and addresses a long-running U.S. goal to be able to provide the full population with protection. Bavarian Nordic CEO Paul Chaplin said on a Wednesday conference call the vaccine is the “result of a fifteen-year partnership” between the U.S. government and the company.

The ACAM2000 made by Emergent BioSolutions:

Sanofi offloads smallpox vaccine business to Emergent BioSolutions in $125M deal

While Sanofi is currently transferring the upstream portion of the vaccine’s manufacturing process from Austria to the U.S. site, an FDA license is expected to arrive in about six months, Abdun-Nabi said during a conference call on July 14. Once approved, the new site will represent another production milestone for Emergent since last August, when the FDA approved the company’s large-scale facility based in Lansing, Michigan, for the manufacture of its anthrax vaccine BioThrax.

Under a 10-year agreement, the Gaithersburg, Maryland-based biotech will also use the Canton facility to manufacture Sanofi’s Japanese encephalitis virus vaccine, according to an SEC filing.

The addition of ACAM2000 will expand Emergent’s class-exclusive portfolio of products to five, and the purchase complements the company’s offerings as it already has VIGIV, the only FDA-licensed med for certain complications from smallpox vaccination.

The same Emergent BioSolutions that received preferential contracts for COVID-19 vaccines from Robert Kadlec because of the enduring partnership between Robert Kadlec and the late Fuad El-Hibri, in spite of Emergent BioSolutions' poor quality control:

Dr. Robert Kadlec: How the Czar of Biowarfare Funnels Billions to Friends in the Vaccine Industry

How was Emergent able to command such high prices from the government? 

Monopoly power. No-bid contracts, facilitated by friends in government. Buyouts of competitors. Unparalleled spending on armies of former-military-turned-lobbyists like the admiral who helped El-Hibri corner the market on the anthrax vaccine back in the 1990s. 

It didn't hurt that Kadlec was a former Emergent consultant and founding partner with El-Hibri of the biodefense company East West Protection.

The same Emergent BioSolutions that renamed themselves from BioPort, after the Anthrax vaccine fiasco that occurred right after Amerithrax. There is some evidence that Gulf War Syndrome is linked to anthrax vaccines:

Before the pandemic, top contractor received billions from government to help prepare the nation for biowarfare

As it races to create a vaccine for the novel coronavirus, the Trump administration this month announced that one of its largest pandemic-related contracts would go to a little-known biodefense company named Emergent BioSolutions. “Emergent’s manufacturing capabilities will pave the way,” Health and Human Services Secretary Alex Azar said in a statement.

The $628 million deal to help manufacture an eventual vaccine cemented Emergent’s status as the highest-paid and most important contractor to the HHS office responsible for preparing for public health threats and maintaining the government’s stockpile of emergency medical supplies.

Emergent has long been the government’s sole provider of BioThrax, a vaccine for anthrax poisoning. But over the past decade, the company has acquired biodefense competitors and treatments for smallpox, botulism and other threats for which there is no market outside of government.

Anthrax and Gulf War Illness (GWI): Evidence for the Presence of Harmful Anthrax Antigen PA63 In the Serum of Veterans with GWI - JNN

Gulf War Illness (GWI) is a multisystem disorder of unknown etiology that has afflicted many veterans of the 1990-91 Gulf War who have sustained progressively worsening health since the war1. Recent studies have demonstrated the presence of active inflammation in GWI2,3 and, in addition, a positive association of the levels of C-reactive protein (CRP), an inflammatory marker, with GWI symptom severity3. Moreover, we have shown that GWI serum contains substances that are harmful to neural cultures4`, a detrimental effect that can be prevented by serum of healthy GW veterans4 and partially so by pooled human immunoglobulin G (IgG)5. Although possible exposure to environmental toxins in war theater has been traditionally blamed for GWI6, the evidence above3-5 and the fact that the disease also afflicted nondeployed veterans7, point to other causes, including the vaccines administered to GW veterans4,5,7, such as the vaccine against anthrax. Here we present, for the first time, evidence indicating the presence of the harmful anthrax protective antigen PA63 in the serum of 15 veterans suffering from GWI, as follows. First, we confirmed that the addition of GWI serum to the culture had a detrimental effect, including decreased cell spreading and increased cell apoptosis, as reported previously4. And second, we found that the concomitant addition of specific polyclonal or monoclonal antibodies against PA63 had a remarkable protective effect on N2A cultures, significantly ameliorating cell spreading and reducing cell apoptosis. These results document that the adverse effects of GWI serum on neural cultures are due, in part, to persistent pathogens derived from the anthrax vaccine. We hypothesize that these anthrax pathogens persisted in the blood of the GWI veterans tested because of inability of those veterans to make antibodies against them, probably due to lack of Human Leukocyte Antigen (HLA) protection8. Finally, our findings point to a possible successful intervention in GWI consisting in neutralizing (by administering specific antibodies) and/or removing (by plasmapheresis) those harmful anthrax antigens.

The same BioPort that was spun off from DynPort, which was a joint venture of DynCorp, the US mercenary company, and Porton in the UK:

A Killer Enterprise: How One of Big Pharma’s Most Corrupt Companies Plans to Corner the Covid-19 Cure Market

That same year, perennial US defense contractor, Dyncorp, went into business with a shadowy group of biotech entrepreneurs from across the pond, forming the DynPort Vaccine Company, LLC., a combination of DynCorp’s name with that of its UK-based partner, Porton International, Inc. The latter company’s president, Zsolt Harsanyi, would also lead DynPort as the British firm began to lay the groundwork for its second attempt at securing a crucial monopoly within the American biotech space.

The same DynCorp who have a long history of engaging in human trafficking while carrying out contracts for the US State Department:

It's Déjà Vu for DynCorp All Over Again

Put bluntly, DynCorp was involved in a sex slavery scandal in Bosnia in 1999, with its employees accused of rape and the buying and selling of girls as young as 12. Dyncorp, hired to perform police duties for the UN and aircraft maintenance for the US Army, were implicated in prostituting the children, whereas the company's Bosnia site supervisor filmed himself raping two women. A number of employees were transferred out of the country, but with no legal consequences for them.

Just a Drill

Just like with Event 201, nonprofit foundations connected to the US biodefense network have conducted drills that presaged all of this.

Did You Know That A 2021 Report Predicted The Monkeypox Outbreak On May 15th 2022 ? Both Companies Involved In The Report Have Received Millions From The Bill & Melinda Gates Foundation.

The NTI was founded by Sam Nunn and Ted Turner:

NTI - Sam Nunn Co-Founder, Co-Chair, and Strategic Advisor

During his tenure in the U.S. Senate, Nunn served as chairman of the Senate Armed Services Committee and the Permanent Subcommittee on Investigations. He also served on the Intelligence and Small Business Committees. His legislative achievements include the landmark Department of Defense Reorganization Act, drafted with the late Senator Barry Goldwater, and the Nunn-Lugar Cooperative Threat Reduction Program, which provided assistance for more than 20 years to Russia and the former Soviet republics for securing and destroying their excess nuclear, biological and chemical weapons.

Yes, the same Sam Nunn that the Nunn-Lugar Act is named after:

The Nunn‐​Lugar Act: A Wasteful and Dangerous Illusion

After the breakup of the Soviet Union in late 1991, four suddenly independent republics (Russia, Ukraine, Kazakhstan, and Belarus) inherited thousands of Soviet nuclear weapons. The abrupt decentralization of control over the Soviet nuclear arsenal, together with well‐​founded concerns about the leadership and stability of the newly independent states, greatly alarmed Washington. Sen. Sam Nunn (D‑Ga.) said of the situation, “I know of no more urgent national security challenge confronting our nation, nor do I know of any greater opportunity … to reduce the dangers confronting us.”[1] Led by Nunn and Sen. Richard Lugar (R‑Ind.), Congress passed the Soviet Nuclear Threat Reduction Act of 1991.[2] The Senate voted 86 to 8 in favor of the legislation‐​which came to be known as the Nunn‐​Lugar Act‐​because even the most stalwart opponents of U.S. foreign aid saw the value of the emergency effort to help the former Soviet republics secure and destroy their excess weapons of mass destruction.

The act, which was funded by a congressionally authorized transfer of $400 million from Department of Defense (DOD) operations and maintenance accounts to Nunn‐​Lugar projects in fiscal year 1992, focused on weapon destruction and security, specifically,

• destroying nuclear, chemical, and other weapons;

• transporting, storing, disabling, and safeguarding weapons to be destroyed; and

• establishing verifiable proliferation safeguards.

The same Nunn-Lugar Cooperative Threat Reduction program that put DTRA in control of a bunch of foreign biolabs where shady research could be conducted with minimal oversight with the money laundered by groups like EcoHealth Alliance, Metabiota, and Labyrinth Global Health:

The Department of Defense’s Cooperative Threat Reduction Program - Biological Threat Reduction Program Activities in Ukraine

The United States, through BTRP, has invested approximately $200 million in Ukraine since 2005, supporting 46 Ukrainian laboratories, health facilities, and diagnostic sites. BTRP has improved Ukraine’s biological safety, security and surveillance for both human and animal health. By supporting safer and more effective disease detection, this assistance directly improved Ukraine’s COVID-19 response. BTRP partners with the World Health Organization, the World Organization for Animal Health, the U.S. Centers for Disease Control and Prevention and other health institutions in providing this assistance.

DoD’s CTR Program began its biological work with Ukraine to reduce the risk posed by the former Soviet Union’s illegal biological weapons program, which left Soviet successor states with unsecured biological materials after the fall of the USSR. DoD’s CTR program works with many partner countries to reduce the threat that pathogens could be misused, stolen or accidentally released. DoD even worked closely with Russia and within Russia in laboratories owned by Russia until 2014.

DoD CTR has worked cooperatively and peacefully with the government of Ukraine to increase biosecurity and biosafety at these sites to ensure pathogens do not pose a risk to the people of Ukraine or the region. The biosafety and biosecurity capacities that DoD has provided are in keeping with those required by the WHO IHR.

Isn’t it amazing how easy it is to utterly dismantle these people with a few casual Google, DuckDuckGo, and Yandex searches?

No wonder they’re desperate for algorithmic censorship of search results.

-Spartacus

This article is licensed under CC BY-SA 4.0. To view a copy of this license, visit http://creativecommons.org/licenses/by-sa/4.0/